202 related articles for article (PubMed ID: 19775297)
1. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
Gloghini A; Buglio D; Khaskhely NM; Georgakis G; Orlowski RZ; Neelapu SS; Carbone A; Younes A
Br J Haematol; 2009 Nov; 147(4):515-25. PubMed ID: 19775297
[TBL] [Abstract][Full Text] [Related]
2. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Buglio D; Mamidipudi V; Khaskhely NM; Brady H; Heise C; Besterman J; Martell RE; MacBeth K; Younes A
Br J Haematol; 2010 Nov; 151(4):387-96. PubMed ID: 20880107
[TBL] [Abstract][Full Text] [Related]
3. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
4. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.
Amengual JE; Johannet P; Lombardo M; Zullo K; Hoehn D; Bhagat G; Scotto L; Jirau-Serrano X; Radeski D; Heinen J; Jiang H; Cremers S; Zhang Y; Jones S; O'Connor OA
Clin Cancer Res; 2015 Oct; 21(20):4663-75. PubMed ID: 26116270
[TBL] [Abstract][Full Text] [Related]
5. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
6. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
[TBL] [Abstract][Full Text] [Related]
8. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
9. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia.
Hackanson B; Rimmele L; Benkißer M; Abdelkarim M; Fliegauf M; Jung M; Lübbert M
Leuk Res; 2012 Aug; 36(8):1055-62. PubMed ID: 22464548
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
12. HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt's Lymphoma Cells by Impeding the Cell Cycle.
Ma XJ; Xu G; Li ZJ; Chen F; Wu D; Miao JN; Zhan Y; Fan Y
Curr Med Sci; 2019 Apr; 39(2):228-236. PubMed ID: 31016515
[TBL] [Abstract][Full Text] [Related]
13. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S
J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976
[TBL] [Abstract][Full Text] [Related]
14. A novel class of small molecule inhibitors of HDAC6.
Inks ES; Josey BJ; Jesinkey SR; Chou CJ
ACS Chem Biol; 2012 Feb; 7(2):331-9. PubMed ID: 22047054
[TBL] [Abstract][Full Text] [Related]
15. HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes.
Noack M; Leyk J; Richter-Landsberg C
Glia; 2014 Apr; 62(4):535-47. PubMed ID: 24464872
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.
North BJ; Almeciga-Pinto I; Tamang D; Yang M; Jones SS; Quayle SN
PLoS One; 2017; 12(3):e0173507. PubMed ID: 28264055
[TBL] [Abstract][Full Text] [Related]
17. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
18. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
19. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
Bobrowicz M; Dwojak M; Pyrzynska B; Stachura J; Muchowicz A; Berthel E; Dalla-Venezia N; Kozikowski M; Siernicka M; Miazek N; Zapala P; Domagala A; Bojarczuk K; Malenda A; Barankiewicz J; Graczyk-Jarzynka A; Zagozdzon A; Gabrysiak M; Diaz JJ; Karp M; Lech-Maranda E; Firczuk M; Giannopoulos K; Efremov DG; Laurenti L; Baatout D; Frenzel L; Malinowska A; Slabicki M; Zenz T; Zerrouqi A; Golab J; Winiarska M
Blood; 2017 Oct; 130(14):1628-1638. PubMed ID: 28830887
[TBL] [Abstract][Full Text] [Related]
20. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
